{"title":"卡维地洛和匹伐他汀对泰乐菌素诱导的 Wistar 大鼠高脂血症的抗高脂血症活性的比较评价","authors":"Md. Akbar , Hasan Ali , Md. Azizur Rahman","doi":"10.1016/j.ipha.2023.11.009","DOIUrl":null,"url":null,"abstract":"<div><p>Aim of the study was designed to investigate the antihyperlipidemic activity of carvedilol and pitavastatin in tyloxapol-induced hyperlipidemia in Wistar rats. The rats were randomly divided into 6 groups. The vehicle control group-I received 2 mL of normal saline for eight days. The pathological control group-II received tyloxapol (400 mg/kg) on 8th day. The treated group-III received 10 mg/kg carvedilol and group-IV received 20 mg/kg carvedilol for eight days and tyloxapol (400 mg/kg) on the 8th day. The group-V received pitavastatin (0.3 mg/kg) for eight days and tyloxapol (400 mg/kg) on the 8th day. The group-VI received carvedilol (20 mg/kg) only for eight days. After eight days of treatment, triglycerides, total cholesterol, high-density lipoprotein, very low-density lipoprotein, thiobarbituric acid reactive substances, and glutathione were estimated in the serum and myocardial tissues along with DNA fragmentation of the liver tissue using gel-electrophoresis. Oral administration of carvedilol to tyloxapol-induced hyperlipidemic rats normalized the changes in the above parameters in a dose dependent manner. Hence, carvedilol with pitavastatin has antihyperlipidemic activity in tyloxapol-induced hyperlipidemia in Wistar rats.</p></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"2 2","pages":"Pages 226-231"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949866X23001235/pdfft?md5=8b316c7007423929357be787f7e0c207&pid=1-s2.0-S2949866X23001235-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Comparative evaluation of carvedilol and pitavastatin for antihyperlipidemic activity in tyloxapol-induced hyperlipidemia in Wistar rats\",\"authors\":\"Md. Akbar , Hasan Ali , Md. Azizur Rahman\",\"doi\":\"10.1016/j.ipha.2023.11.009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Aim of the study was designed to investigate the antihyperlipidemic activity of carvedilol and pitavastatin in tyloxapol-induced hyperlipidemia in Wistar rats. The rats were randomly divided into 6 groups. The vehicle control group-I received 2 mL of normal saline for eight days. The pathological control group-II received tyloxapol (400 mg/kg) on 8th day. The treated group-III received 10 mg/kg carvedilol and group-IV received 20 mg/kg carvedilol for eight days and tyloxapol (400 mg/kg) on the 8th day. The group-V received pitavastatin (0.3 mg/kg) for eight days and tyloxapol (400 mg/kg) on the 8th day. The group-VI received carvedilol (20 mg/kg) only for eight days. After eight days of treatment, triglycerides, total cholesterol, high-density lipoprotein, very low-density lipoprotein, thiobarbituric acid reactive substances, and glutathione were estimated in the serum and myocardial tissues along with DNA fragmentation of the liver tissue using gel-electrophoresis. Oral administration of carvedilol to tyloxapol-induced hyperlipidemic rats normalized the changes in the above parameters in a dose dependent manner. Hence, carvedilol with pitavastatin has antihyperlipidemic activity in tyloxapol-induced hyperlipidemia in Wistar rats.</p></div>\",\"PeriodicalId\":100682,\"journal\":{\"name\":\"Intelligent Pharmacy\",\"volume\":\"2 2\",\"pages\":\"Pages 226-231\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2949866X23001235/pdfft?md5=8b316c7007423929357be787f7e0c207&pid=1-s2.0-S2949866X23001235-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Intelligent Pharmacy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2949866X23001235\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Intelligent Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949866X23001235","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
本研究旨在探讨卡维地洛和匹伐他汀对泰乐沙醇诱导的 Wistar 大鼠高脂血症的抗高脂血症活性。大鼠随机分为 6 组。载体对照组-I 接受 2 mL 生理盐水,为期 8 天。病理对照组-II在第8天接受泰乐沙醇(400毫克/千克)治疗。治疗组-III接受10毫克/千克卡维地洛治疗,组-IV接受20毫克/千克卡维地洛治疗8天,并在第8天接受tyloxapol(400毫克/千克)治疗。第五组连续八天服用匹伐他汀(0.3 毫克/千克),第八天服用泰乐沙波尔(400 毫克/千克)。第六组只接受卡维地洛(20 毫克/千克)治疗八天。治疗八天后,使用凝胶电泳法对血清和心肌组织中的甘油三酯、总胆固醇、高密度脂蛋白、极低密度脂蛋白、硫代巴比妥酸活性物质和谷胱甘肽以及肝组织的 DNA 片段进行了估测。给tyloxapol诱导的高脂血症大鼠口服卡维地洛,可使上述参数的变化趋于正常,且呈剂量依赖性。因此,卡维地洛联合匹伐他汀对泰乐沙醇诱导的 Wistar 大鼠高脂血症具有抗高脂血症活性。
Comparative evaluation of carvedilol and pitavastatin for antihyperlipidemic activity in tyloxapol-induced hyperlipidemia in Wistar rats
Aim of the study was designed to investigate the antihyperlipidemic activity of carvedilol and pitavastatin in tyloxapol-induced hyperlipidemia in Wistar rats. The rats were randomly divided into 6 groups. The vehicle control group-I received 2 mL of normal saline for eight days. The pathological control group-II received tyloxapol (400 mg/kg) on 8th day. The treated group-III received 10 mg/kg carvedilol and group-IV received 20 mg/kg carvedilol for eight days and tyloxapol (400 mg/kg) on the 8th day. The group-V received pitavastatin (0.3 mg/kg) for eight days and tyloxapol (400 mg/kg) on the 8th day. The group-VI received carvedilol (20 mg/kg) only for eight days. After eight days of treatment, triglycerides, total cholesterol, high-density lipoprotein, very low-density lipoprotein, thiobarbituric acid reactive substances, and glutathione were estimated in the serum and myocardial tissues along with DNA fragmentation of the liver tissue using gel-electrophoresis. Oral administration of carvedilol to tyloxapol-induced hyperlipidemic rats normalized the changes in the above parameters in a dose dependent manner. Hence, carvedilol with pitavastatin has antihyperlipidemic activity in tyloxapol-induced hyperlipidemia in Wistar rats.